• Indian Indices
  • Global Indices
  • Commodities
  • Currency
Sensex
  • Sensex
  • Nifty
{{x.close_price| number:2}} {{x.netchg| number:2}} ({{x.perchg | number:2}}%)
Open - {{x.open | number:2}}
Prev Close - {{x.prevclose|number:2}}
Today's High - {{x.high|number:2}}
Today's Low - {{x.low|number:2}}
Advances/Declines (30 Companies)
  • 1D
  • 1W
  • 1M
  • 1Yr
  • 5Yr
{{x.upd_time}}
FTSE 100
  • FTSE 100
  • DJIA
  • NIKKEI 225
  • HANG SENG
{{x.Date}}
{{x.close| number:2}} {{x.Chg | number:2}} ({{x.PChg | number:2}}%)
Open - {{x.close | number:2}}
Prev Close - {{x.PrevClose|number:2}}
Gold
  • Gold
  • Silver
  • Crude Oil
  • Copper
{{x.Trd_Date}} ( {{x.Time}} )
{{x.ClosePrice| number:2}} {{x.change| number:2}} ({{x.perchange | number:2}}%)
Exchange - MCX
Open - {{x.Open|number:2}}
Exp Date - {{x.Exp_Date}}
Today's High - {{x.High|number:2}}
Prev. Close - {{x.PrevClose|number:2}}
Today's Low - {{x.Low|number:2}}
USDINR
  • USDINR
  • GBPINR
  • EURINR
  • JPYINR
{{x.Lasttrdtime}} ( {{x.Time}} )
{{x.ltp| number:2}} {{x.PriceDiff| number:2}} ({{x.PerChange | number:2}}%)
Exchange - NSE
Open - {{x.Open|number:2}}
Exp Date - {{x.Expirydate}}
Today's High - {{x.High|number:2}}
Prev. Close - {{x.PrevPrice|number:2}}
Today's Low - {{x.Low|number:2}}
As On 02-Jun-2023 EOD, Market Closed
SENSEX
62,547.11
118.57 (0.19%)
NIFTY
18,534.10
46.35 (0.25%)
    No Companies Visited

Back to news list
  • Torrent Pharma Q3 PAT rises 14% YoY to Rs 283 cr

    On consolidated basis, Torrent Pharmaceuticals' net profit rose 13.7% to Rs 283 crore on 18.17% jump in net revenue from operations to Rs 2,491 crore in Q3 FY23 over Q3 FY22.

    The drug maker's consolidated profit before tax grew 17.4% to Rs 419 crore in Q3 FY23 from Rs 357 crore reported in the same period last year. Gross profit rose 20% year on year to Rs 1,761 crore in Q3 FY23. Operating EBITDA stood at Rs 724 crore in Q3 FY23, registering a growth of 35% from Rs 538 crore recorded in Q3 FY22. Meanwhile, EBITDA margin improved to 29% in Q3 FY23 as compared to 26% reported in the corresponding quarter previous year. India revenues were at Rs 1,259 crore in Q3 FY23, rising 17%, it includes revenue from integration of Curatio Healthcare. As per AIOCD secondary data, Torrent's growth for the quarter was 12% versus Indian Pharmaceutical Market (IPM) growth of 12%. The field force has been further expanded and MR strength now stands at 5,300 including Curatio divisions, said the company.

    Brazil revenue surged 36% YoY to Rs 248 crore in Q3 FY23. Constant currency revenue at R$ 159 million was up by 17%. As per secondary data set, Torrent's growth is 19% versus BGx market growth of 13% for the quarter ended November 2022. The pharma company said that the growth was aided by performance of top brands and market share gain and strong momentum in generic segment,.

    During the quarter, US revenue stood at Rs 291 crores, up by 24%. Constant currency revenue was at $35 million, rising 13%. As on 31 December 2022, 48 ANDAs were pending approval with USFDA and 3 tentative approvals were received. During the quarter, 1 ANDAs was filed & 1 ANDAs was approved.

    Germany revenue was at Rs 241 crore in Q3 FY23, up by 1%. Constant currency revenue were Euro 29 million, up by 4%. Sequential recovery in Germany was complemented new tenders and growth of OTC segment.

    Meanwhile, the company's board has approved an interim dividend of Rs 14 per equity share. The dividend is expected to be paid/ dispatched on or around 14 February 2023.

    Torrent Pharmaceuticals is the flagship Company of the Torrent Group. It is ranked 7th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of cardiovascular (CV), gastro intestinal (GI), central nervous system (CNS), and vitamins minerals nutritionals (VMN).

    Shares of Torrent Pharmaceuticals declined 1.61% to Rs 1,532.40 on the BSE.



    Back to news list
Previous Stories :
More






Hot Pursuit News

Quick Links

Market Statistics

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

The power of the database is harnessed by our fired-up reporters to generate interesting ideas. The reader-friendly presentation of the idea, supplemented by relevant data and information, can be accessed online through Capita Telefolio and Telefolio Gold. These ideas are used by individual investors as well as institutional investors to do further research and stay ahead.

Capital Market Publishers India Pvt. Ltd.

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071.
91-22-25229720
9769005430
Kindly note www.capitalmarket.com does not send any mobile SMS, whatsapp or twitter messages
giving any kind of stock recommendations.
For Capital Market Magazine queries mail to : subscription@capitalmarket.com
For Capital Market Online Products related queries mail to : financeshop@capitalmarket.com
For any other Capital Market Website related Queries mail to : info@capitalmarket.com
To advertise on Capital Market Websites & Capital Market Fortnightly magazine mail to : advt@capitalmarket.com
Flash News 03-Jun-2023
  •  ( 15:57) NTPC arm declares commercial operation of last part of Nokhra Solar PV project  
  •  ( 15:00) Vedanta subsidiary enters into PDA with Serentica Renewables India  
  •  ( 12:36) Zydus Life gets zero observation from USFDA for Ahmedabad facility  
  •  ( 10:25) CRISIL reaffirms rating of Tata Chemicals at 'A1+'  
  •  ( 10:15) US FDA classifies Indoco Remedies' Goa plant inspection as OAI  
  •  ( 10:15) Minda Corp board OKs proposal to raise funds up to Rs 600 crore  
  •  ( 09:59) TechM to divest stake in Brasil-based step-down subsidiary  
  •  ( 09:14) IRDAI asks SBI Life to take over troubled Sahara's biz  
Show News
02 June 2023 00:00
3235.15
(-0.16 %)
926.00
(0.71 %)
7023.00
(-0.25 %)
1456.55
(0.42 %)
836.20
(0.98 %)
2646.30
(0.02 %)
1136.90
(-0.38 %)
1606.15
(0.13 %)
2716.35
(0.69 %)
937.05
(0.11 %)
1288.10
(-0.24 %)
1298.65
(-1.58 %)
443.20
(0.77 %)
1939.75
(0.58 %)
2235.25
(1.19 %)
1341.05
(1.68 %)
9488.80
(1.73 %)
22040.60
(0.83 %)
174.40
(0.06 %)
234.60
(0.73 %)
2454.95
(-0.29 %)
587.20
(0.79 %)
999.35
(1.20 %)
535.75
(0.09 %)
108.00
(1.93 %)
3304.40
(-0.57 %)
1122.30
(0.12 %)
2859.60
(1.16 %)
7849.40
(0.09 %)
404.80
(-0.60 %)
Sensex 5min and Nifty 15min delayed as on .
Show Ticker
Rotate your device

Rotate your device

For the best experience please go back to portrait mode.